Gruppo Italiano Malattie EMatologiche dell'Adulto: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 22 Leukemia, Lymphocytic, Chronic, B-Cell studies with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. 5 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 10No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Biological and Clinical Efficacy of Shingrix in Patients With CLLNot yet recruitingNCT06364033Not applicable
• Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNot yet recruitingNCT06084923
• Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
• Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
• Study on the Diagnosis and Management of CLL in Italy by GIMEMARecruitingNCT04867915
• Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01403246Phase 1/2Results posted
• Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
• Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic LeukemiaCompletedNCT00462332Phase 2Results posted
• Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLLActive, not recruitingNCT05478512Phase 2
• Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
• Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyActive, not recruitingNCT04282811
• The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
• Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyCompletedNCT03545035
• The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibCompletedNCT03528941
• Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
• Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramCompletedNCT02582320
• Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaCompletedNCT02491398
• Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
• Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
• Occupational Status and Hematological DiseaseCompletedNCT02057185
• Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL PatientsStatus unknownNCT01862445
• Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.CompletedNCT01762202Phase 2